Supplements news and information

Johnson & Johnson said it would pay up to $1 billion for Aragon Pharmaceuticals and its experimental drugs for prostate cancer, to bolster J&J's role in the field after it acquired another experimental prostate-cancer treatment four years ago that has become a leading brand.
FULL STORY »

Variation in hospital performance is alive and well, as shown by Truven Health Analytics' studies conducted exclusively for Modern Healthcare. Variation continues to be a problem, despite productive efforts of hundreds of organizations and hundreds of thousands of healthcare professionals dedicated...
FULL STORY »

The watershed moment for OhioHealth came several years ago, during a meeting of the health system's quality of care committee, when senior leaders distributed a detailed list of all of the serious safety events that had occurred at OhioHealth's eight hospitals during the previous year.
FULL STORY »

Major teaching hospitals have the lowest mortality rate of all hospital categories, according to a new study conducted by Truven Health Analytics. But they also have significantly higher incidence of adverse patient-safety events and complications.
FULL STORY »

In an era of transparency, government agencies and not-for-profit advocacy groups are publishing a growing amount of data about providers' performance on outcomes, quality measures, pricing and patient satisfaction.
FULL STORY »

The CMS and Medicare beneficiaries could have saved an estimated $510 million on drugs used to treat end-stage renal disease in 2011 if the reimbursement rate more accurately reflected current usage of these drugs, according to a report from HHS' inspector general's office.
FULL STORY »

Persistent drug shortages have led healthcare providers, pharmacists and others to debate the role of compounding pharmacies as alternative sources of drugs in short supply.
FULL STORY »

A lot can change in a year. Last March, Walgreen Co. was simply a domestic drugstore chain. Today, the Deerfield, Ill.-based company is part of an international juggernaut through a partnership with Europe's leading pharmacy chain Alliance Boots GmbH and, with a new 10-year deal with drug...
FULL STORY »

The Food and Drug Administration plans to loosen the rules for approving new treatments for Alzheimer's disease.
FULL STORY »

About 80 million Americans suffer from heart disease, the nation's No. 1 killer, and most are on multiple drugs. Some cardiologists think prescribing has gotten out of hand.
FULL STORY »